Evidence map›Paper›PMID 33012204›Full record

ArticleHypertension (Dallas, Tex. : 1979)2020

Mitochondrial Isolevuglandins Contribute to Vascular Oxidative Stress and Mitochondria-Targeted Scavenger of Isolevuglandins Reduces Mitochondrial Dysfunction and Hypertension.

Anna Dikalova, Vladimir Mayorov, Liang Xiao, Alexander Panov, Venkataraman Amarnath, Irene Zagol-Ikapitte, Aurelia Vergeade, Mingfang Ao, Valery Yermalitsky, Rafal R Nazarewicz and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Reactive oxygen species in hypertension.Nature reviews. Cardiology · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Mitophagy in hypertension-mediated organ damage.Frontiers in cardiovascular medicine · 2023
    Review
  14. Review
  15. Oxidative Regulation of Vascular CaAntioxidants (Basel, Switzerland) · 2022
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Anna DikalovaFrom the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).
Vladimir MayorovMercer University School of Medicine, Macon, Georgia (V.M.).
Liang XiaoFrom the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).
Alexander PanovScientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russian Federation (A.P.).
Venkataraman AmarnathFrom the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).
Irene Zagol-IkapitteFrom the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).
Aurelia VergeadeFrom the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).
Mingfang AoFrom the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).
Valery YermalitskyFrom the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).
Rafal R NazarewiczFrom the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).
Olivier BoutaudFrom the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).
Marcos G LopezFrom the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).
Frederic T BillingsFrom the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).
Sean DaviesFrom the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).
L Jackson RobertsFrom the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).
David G HarrisonFrom the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).
Sergey DikalovFrom the Vanderbilt University Medical Center, Nashville, TN (A.D., L.X., V.A., I.Z.-I., A.V., M.A., V.Y., R.R.N., O.B., M.G.L., F.T.B., S. Davies, L.J.R., D.G.H., S. Dikalov).
Vanderbilt University Medical Center · USMercer University · USScientific Center of Family Health Problems and Human Reproduction · RU

Funding

The Role of Inflammation in Cardiovascular DiseaseP01HL129941 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARRISON, DAVID G · 2016 to 2020
$12.4M
Mechanisms of Immune Activation in HypertensionR35HL140016 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARRISON, DAVID G · 2018 to 2024
$5.3M
Hyper-oxygenation, oxidative stress, and kidney injury following cardiac surgeryR01GM112871 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BILLINGS, FREDERIC TREMAINE · 2015 to 2019
$1.8M
Targeting Mitochondrial Cyclophilin D in Vascular Oxidative Stress and HypertensionR01HL144943 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DIKALOV, SERGEY · 2019 to 2022
$1.7M
Sirtuin 3 Impairment and SOD2 Acetylation in Oxidative Stress and HypertensionR01HL124116 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DIKALOV, SERGEY · 2015 to 2018
$1.6M
Perioperative Oxygenation, Endothelial Dysfunction, and Organ Injury in Cardiac SurgeryK23GM129662 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LOPEZ, MARCOS G · 2018 to 2022
$764k
NHLBI NIH HHS P01 HL129941NHLBI NIH HHS R01 HL124116NHLBI NIH HHS R01 HL144943NHLBI NIH HHS R35 HL140016NIGMS NIH HHS K23 GM129662NIGMS NIH HHS R01 GM112871
6 · The paper itself

Abstract

Hypertension remains a major health problem in Western Societies, and blood pressure is poorly controlled in a third of patients despite use of multiple drugs. Mitochondrial dysfunction contributes to hypertension, and mitochondria-targeted agents can potentially improve treatment of hypertension. We have proposed that mitochondrial oxidative stress produces reactive dicarbonyl lipid peroxidation products, isolevuglandins, and that scavenging of mitochondrial isolevuglandins improves vascular function and reduces hypertension. To test this hypothesis, we have studied the accumulation of mitochondrial isolevuglandins-protein adducts in patients with essential hypertension and Ang II (angiotensin II) model of hypertension using mass spectrometry and Western blot analysis. The therapeutic potential of targeting mitochondrial isolevuglandins was tested by the novel mitochondria-targeted isolevuglandin scavenger, mito2HOBA. Mitochondrial isolevuglandins in arterioles from hypertensive patients were 250% greater than in arterioles from normotensive subjects, and ex vivo mito2HOBA treatment of arterioles from hypertensive subjects increased deacetylation of a key mitochondrial antioxidant, SOD2 (superoxide dismutase 2). In human aortic endothelial cells stimulated with Ang II plus TNF (tumor necrosis factor)-α, mito2HOBA reduced mitochondrial superoxide and cardiolipin oxidation, a specific marker of mitochondrial oxidative stress. In Ang II-infused mice, mito2HOBA diminished mitochondrial isolevuglandins-protein adducts, raised Sirt3 (sirtuin 3) mitochondrial deacetylase activity, reduced vascular superoxide, increased endothelial nitric oxide, improved endothelium-dependent relaxation, and attenuated hypertension. Mito2HOBA preserved mitochondrial respiration, protected ATP production, and reduced mitochondrial permeability pore opening in Ang II-infused mice. These data support the role of mitochondrial isolevuglandins in endothelial dysfunction and hypertension. We conclude that scavenging of mitochondrial isolevuglandins may have therapeutic potential in treatment of vascular dysfunction and hypertension.

Indexed as

Oxidative StressAngiotensin IIAnimalsAntioxidantsArteriolesBlood PressureEssential HypertensionFemaleFree Radical ScavengersHumansLipidsMaleMice, Inbred C57BLMitochondriaSirtuin 3Superoxide DismutaseAngiotensin IIAntioxidantsFree Radical ScavengersisolevuglandinLipidsSirtuin 3Superoxide DismutaseSuperoxide Dismutase 2blood pressuremitochondriaoxidative stressSirtuin 3superoxide dismutase

Identifiers

PMID33012204
PMCPMC7666054
OpenAlexW3084219454

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.